Market Cap N/A
Revenue (ttm) 46.92M
Net Income (ttm) -38.10M
EPS (ttm) N/A
PE Ratio N/A
Forward PE 0.00
Profit Margin -81.20%
Debt to Equity Ratio N/A
Volume 775,700
Avg Vol 145,364
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 80%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclero...

Industry: Biotechnology
Sector: Healthcare
Phone: 778 731 1711
Website: nervgen.com
Address:
112-970 Burrard Street, Unit 1290, Vancouver, Canada
BeefStewart
BeefStewart Aug. 19 at 6:38 PM
from GPT $NGEN: After digging through the full CONNECT SCI dataset, my view is more bullish—but with an important distinction. I think the evidence that NVG-291 does something biologically real is now considerably stronger than the evidence that RESTORE will succeed. Why? The same tiny 10-patient treated cohort produced a significant upper-limb MEP primary endpoint (p=.0155), a meaningful but nonsignificant GRASSP QtP signal, 5/10 vs 1/10 strong QtP responders, supportive reticulospinal findings, durable improvement after dosing stopped, and later blinded gait biomechanics favoring NVG-291 (global p=.0197; 10/10 vs 1/10 gait responders). That convergence across physiology, hand function, gait and patient experience is hard to dismiss—but it is still only 10 treated patients, and some analyses were post-hoc. My rough handicap: biological activity 75–85%; meaningful functional benefit 60–75%; RESTORE success 40–55%. I posted the full reasoning on Yahoo Finance for anyone interested.
1 · Reply
BenUnknown
BenUnknown Aug. 19 at 6:20 PM
0 · Reply
Westjtter
Westjtter Aug. 19 at 6:00 PM
$NGEN Yes our time will come...remember that NGEN is a tiny little company headquartered in Vancouver and is not well know yet to either the medical field or the larger funds and institutions. Everyone here(those that are aware of NGEN) seems to acknowledge the Restore drug is as close as you can get to a miracle for anyone with spinal cord or our neurological injuries. A properly administered ph 3 could prove this for all and send this thing into orbit! Meanwhile the shares are on sale!
1 · Reply
BenUnknown
BenUnknown Aug. 19 at 5:26 PM
$NGEN Just started a position here! Incredibly fascinating therapy and excited for the future trial! Will DCA into this position going forward
0 · Reply
jbh973
jbh973 Aug. 19 at 3:10 PM
$NGEN Thanks to @OldManLogan I believe I jumped onboard here at exactly the right time. Outside of quick flips, I've avoided small cap bios like the plaque as that is the one area I've gotten burned over the years. I see many posts in here from angry people who have been in this one a long time. If I learned anything investing in these type of tickers, a majority of them do indeed fail, or are scams, or just lack proper management. In regards to the latter, the recent infusion of the people NGEN hired so far looks to me like they are helping right the boat. So again, I got in at the right time, & time & patience is all that is required if NVG-291 succeeds, & so far it has. Everything I researched about NGEN over the past few months & the positive & very helpful posts in here scream out to me that this one is a winner. If I can make a boatload of money while being an investor in something that can change peoples lives for the better, it's THE best type of gamble I can make.
0 · Reply
OldManLogan
OldManLogan Aug. 19 at 2:09 PM
$NGEN Hit the nail on the head. This is the very DEFINITION of a miracle drug. There are no other drugs for SCI, nothing, it's a dessert. There is an incomprehensible disconnect between what NVG-291 is capable of and the degree of investors engagement. I do think that changes over the next year as the trial progresses and other indications get announced and start development... I'm very grateful to these individuals for doing these videos and interviews; it's an important part of the investment thesis, these folks are the true ambassadors for NVG-291, over and above the management team.
0 · Reply
jbh973
jbh973 Aug. 19 at 1:33 PM
$NGEN $MRNA - Yet another Phase 3 Grand Slam. This one is a winner. Our time is coming.
0 · Reply
Floridaorange
Floridaorange Aug. 19 at 12:51 PM
$NGEN How the VA isn’t already having this administered to every American vet who needs 24-7 caretaking from being paralyzed on the battlefield is unconscionable to me. Who needs to make a phone call??
1 · Reply
Floridaorange
Floridaorange Aug. 19 at 11:31 AM
$NGEN Serious question - what do you all make of the videos of patients who were in wheelchairs then walking & driving praising NVG-291? https://youtu.be/ip7rVlc2FJg?si=yK-k_4mWs02un5WV Seems awfully unique & encouraging. Aside from the execution of the next steps, on merit alone how much value do you assign to these videos out there??
6 · Reply
aladdinscarpet
aladdinscarpet Aug. 19 at 12:31 AM
$NGEN New nomination for FDA commisioner Heidi Overton https://www.bloomberg.com/news/articles/2026-08-19/trump-taps-white-house-adviser-to-run-fda-after-months-of-tumult?accessToken=eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJzb3VyY2UiOiJTdWJzY3JpYmVyR2lmdGVkQXJ0aWNsZSIsImlhdCI6MTc4NzA5OTI4OCwiZXhwIjoxNzg3NzA0MDg4LCJhcnRpY2xlSWQiOiJUSEVaQTRLSkg2VjQwMCIsImJjb25uZWN0SWQiOiI1OTk0Q0E2QjNEQUM0ODA4OUQ2MDRBRkE4MjQ4Mzg0QSJ9.fLNoCg70Pim4kYSHf7e9NjtvJ224IJfopJ0qegK-vNE
0 · Reply
Latest News on NGEN
NervGen Pharma Earnings release: Q2 2026

Aug 13, 2026, 9:00 AM EDT - 6 days ago

NervGen Pharma Earnings release: Q2 2026


NervGen Pharma initiated with an Outperform at Leerink

2026-07-13T11:45:36.000Z - 5 weeks ago

NervGen Pharma initiated with an Outperform at Leerink


NervGen Pharma initiated with a Buy at TD Cowen

2026-06-11T09:51:08.000Z - 2 months ago

NervGen Pharma initiated with a Buy at TD Cowen


NervGen Pharma files $250M mixed securities shelf

2026-05-26T13:28:30.000Z - 3 months ago

NervGen Pharma files $250M mixed securities shelf


NervGen Pharma Registration statement: Registration filing

May 26, 2026, 8:00 AM EDT - 3 months ago

NervGen Pharma Registration statement: Registration filing


NervGen Pharma 24M share Spot Secondary priced at $2.50

2026-05-22T10:31:38.000Z - 3 months ago

NervGen Pharma 24M share Spot Secondary priced at $2.50


NervGen Pharma secondary being re-offered at $2.50 per share

2026-05-21T23:20:11.000Z - 3 months ago

NervGen Pharma secondary being re-offered at $2.50 per share


NervGen Pharma announces common share offering, no amount given

2026-05-21T20:06:04.000Z - 3 months ago

NervGen Pharma announces common share offering, no amount given


NervGen Announces Proposed Public Offering of Securities

May 21, 2026, 4:01 PM EDT - 3 months ago

NervGen Announces Proposed Public Offering of Securities


NervGen Pharma Slides: Corporate presentation

May 21, 2026, 7:00 AM EDT - 3 months ago

NervGen Pharma Slides: Corporate presentation


NervGen Pharma reports Q1 EPS (2c), consensus (7c)

2026-05-18T11:26:55.000Z - 3 months ago

NervGen Pharma reports Q1 EPS (2c), consensus (7c)


NervGen Pharma Earnings release: Q1 2026

May 18, 2026, 7:00 AM EDT - 3 months ago

NervGen Pharma Earnings release: Q1 2026


NervGen Pharma appoints Keith Vendola as CFO

2026-04-27T11:49:46.000Z - 4 months ago

NervGen Pharma appoints Keith Vendola as CFO


NervGen Pharma initiated with a Buy at H.C. Wainwright

2026-04-27T10:13:14.000Z - 4 months ago

NervGen Pharma initiated with a Buy at H.C. Wainwright


NervGen Pharma Transcript: HCW Home with NervGen Conference

Apr 15, 2026, 7:00 AM EDT - 4 months ago

NervGen Pharma Transcript: HCW Home with NervGen Conference


NervGen Pharma initiated with a Buy at Lucid Capital

2026-04-15T10:11:00.000Z - 4 months ago

NervGen Pharma initiated with a Buy at Lucid Capital


NervGen Pharma price target raised to $12 from $10 at Maxim

2026-04-08T19:20:16.000Z - 4 months ago

NervGen Pharma price target raised to $12 from $10 at Maxim


NervGen Pharma Annual report: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 5 months ago

NervGen Pharma Annual report: Q4 2025


NervGen Pharma Earnings release: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 5 months ago

NervGen Pharma Earnings release: Q4 2025


NervGen Pharma to delist shares from TSX

2026-03-12T21:20:54.000Z - 5 months ago

NervGen Pharma to delist shares from TSX


NervGen Pharma price target raised to C$6.75 from C$5 at Stifel

2026-03-05T17:15:53.000Z - 5 months ago

NervGen Pharma price target raised to C$6.75 from C$5 at Stifel


NervGen Pharma to Participate at Upcoming Investor Conferences

Feb 18, 2026, 7:30 AM EST - 6 months ago

NervGen Pharma to Participate at Upcoming Investor Conferences


NervGen Pharma Begins Trading on Nasdaq Today

Jan 8, 2026, 6:30 AM EST - 7 months ago

NervGen Pharma Begins Trading on Nasdaq Today


NervGen Pharma Registration statement: Registration filing

Jan 7, 2026, 7:00 AM EST - 8 months ago

NervGen Pharma Registration statement: Registration filing


NervGen Pharma Registration statement: Registration filing

Dec 17, 2025, 7:00 AM EST - 8 months ago

NervGen Pharma Registration statement: Registration filing


NervGen Pharma Announces Proposed Amendment to Warrants

Dec 12, 2025, 7:51 PM EST - 8 months ago

NervGen Pharma Announces Proposed Amendment to Warrants


NervGen Pharma Earnings release: Q3 2025

Nov 25, 2025, 7:00 AM EST - 9 months ago

NervGen Pharma Earnings release: Q3 2025


NervGen Pharma Earnings release: Q2 2025

Aug 26, 2025, 7:00 AM EDT - 1 year ago

NervGen Pharma Earnings release: Q2 2025


NervGen Pharma Grants Stock Options

May 16, 2025, 4:30 PM EDT - 1 year ago

NervGen Pharma Grants Stock Options


NervGen Pharma Earnings release: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

NervGen Pharma Earnings release: Q1 2025


NervGen Pharma Earnings release: Q4 2024

Apr 3, 2025, 7:00 AM EDT - 1 year ago

NervGen Pharma Earnings release: Q4 2024


NervGen Initiates Expanded Access Policy

Mar 31, 2025, 7:30 AM EDT - 1 year ago

NervGen Initiates Expanded Access Policy


NervGen Pharma to Host Virtual Investor Event

Mar 25, 2025, 8:30 AM EDT - 1 year ago

NervGen Pharma to Host Virtual Investor Event


NervGen Announces "At-The-Market" Equity Program

Dec 20, 2024, 7:30 AM EST - 1 year ago

NervGen Announces "At-The-Market" Equity Program


NervGen Pharma Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

NervGen Pharma Earnings release: Q3 2024


BeefStewart
BeefStewart Aug. 19 at 6:38 PM
from GPT $NGEN: After digging through the full CONNECT SCI dataset, my view is more bullish—but with an important distinction. I think the evidence that NVG-291 does something biologically real is now considerably stronger than the evidence that RESTORE will succeed. Why? The same tiny 10-patient treated cohort produced a significant upper-limb MEP primary endpoint (p=.0155), a meaningful but nonsignificant GRASSP QtP signal, 5/10 vs 1/10 strong QtP responders, supportive reticulospinal findings, durable improvement after dosing stopped, and later blinded gait biomechanics favoring NVG-291 (global p=.0197; 10/10 vs 1/10 gait responders). That convergence across physiology, hand function, gait and patient experience is hard to dismiss—but it is still only 10 treated patients, and some analyses were post-hoc. My rough handicap: biological activity 75–85%; meaningful functional benefit 60–75%; RESTORE success 40–55%. I posted the full reasoning on Yahoo Finance for anyone interested.
1 · Reply
BenUnknown
BenUnknown Aug. 19 at 6:20 PM
0 · Reply
Westjtter
Westjtter Aug. 19 at 6:00 PM
$NGEN Yes our time will come...remember that NGEN is a tiny little company headquartered in Vancouver and is not well know yet to either the medical field or the larger funds and institutions. Everyone here(those that are aware of NGEN) seems to acknowledge the Restore drug is as close as you can get to a miracle for anyone with spinal cord or our neurological injuries. A properly administered ph 3 could prove this for all and send this thing into orbit! Meanwhile the shares are on sale!
1 · Reply
BenUnknown
BenUnknown Aug. 19 at 5:26 PM
$NGEN Just started a position here! Incredibly fascinating therapy and excited for the future trial! Will DCA into this position going forward
0 · Reply
jbh973
jbh973 Aug. 19 at 3:10 PM
$NGEN Thanks to @OldManLogan I believe I jumped onboard here at exactly the right time. Outside of quick flips, I've avoided small cap bios like the plaque as that is the one area I've gotten burned over the years. I see many posts in here from angry people who have been in this one a long time. If I learned anything investing in these type of tickers, a majority of them do indeed fail, or are scams, or just lack proper management. In regards to the latter, the recent infusion of the people NGEN hired so far looks to me like they are helping right the boat. So again, I got in at the right time, & time & patience is all that is required if NVG-291 succeeds, & so far it has. Everything I researched about NGEN over the past few months & the positive & very helpful posts in here scream out to me that this one is a winner. If I can make a boatload of money while being an investor in something that can change peoples lives for the better, it's THE best type of gamble I can make.
0 · Reply
OldManLogan
OldManLogan Aug. 19 at 2:09 PM
$NGEN Hit the nail on the head. This is the very DEFINITION of a miracle drug. There are no other drugs for SCI, nothing, it's a dessert. There is an incomprehensible disconnect between what NVG-291 is capable of and the degree of investors engagement. I do think that changes over the next year as the trial progresses and other indications get announced and start development... I'm very grateful to these individuals for doing these videos and interviews; it's an important part of the investment thesis, these folks are the true ambassadors for NVG-291, over and above the management team.
0 · Reply
jbh973
jbh973 Aug. 19 at 1:33 PM
$NGEN $MRNA - Yet another Phase 3 Grand Slam. This one is a winner. Our time is coming.
0 · Reply
Floridaorange
Floridaorange Aug. 19 at 12:51 PM
$NGEN How the VA isn’t already having this administered to every American vet who needs 24-7 caretaking from being paralyzed on the battlefield is unconscionable to me. Who needs to make a phone call??
1 · Reply
Floridaorange
Floridaorange Aug. 19 at 11:31 AM
$NGEN Serious question - what do you all make of the videos of patients who were in wheelchairs then walking & driving praising NVG-291? https://youtu.be/ip7rVlc2FJg?si=yK-k_4mWs02un5WV Seems awfully unique & encouraging. Aside from the execution of the next steps, on merit alone how much value do you assign to these videos out there??
6 · Reply
aladdinscarpet
aladdinscarpet Aug. 19 at 12:31 AM
$NGEN New nomination for FDA commisioner Heidi Overton https://www.bloomberg.com/news/articles/2026-08-19/trump-taps-white-house-adviser-to-run-fda-after-months-of-tumult?accessToken=eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJzb3VyY2UiOiJTdWJzY3JpYmVyR2lmdGVkQXJ0aWNsZSIsImlhdCI6MTc4NzA5OTI4OCwiZXhwIjoxNzg3NzA0MDg4LCJhcnRpY2xlSWQiOiJUSEVaQTRLSkg2VjQwMCIsImJjb25uZWN0SWQiOiI1OTk0Q0E2QjNEQUM0ODA4OUQ2MDRBRkE4MjQ4Mzg0QSJ9.fLNoCg70Pim4kYSHf7e9NjtvJ224IJfopJ0qegK-vNE
0 · Reply
jbh973
jbh973 Aug. 18 at 7:58 PM
$NGEN Take a peek at $AMLX today. They were at $1..72 a share on 5/31/24. They just aced their P3 trial & are moonshotting today. It will take some time, but that could be us here in the near future. Congrats to all the longs in that one.
1 · Reply
rwelsh633
rwelsh633 Aug. 18 at 6:19 PM
$NGEN Anyone else buying options? I have some $2.50 call for January $5 calls for February. I’d assumed we get some testimony’s by then🤞🏼
1 · Reply
Tarquinjones
Tarquinjones Aug. 18 at 5:17 PM
$NGEN I would not be short this. “As a former longtime leader at the FDA, I encourage patient advocacy organizations like BreakThru SCI to step forward and help shape the regulatory landscape by giving voice and perspective on what is meaningful to those most affected,” said Janet Woodcock, M.D., former Acting Commissioner of the Food and Drug Administration (FDA), who will offer remarks at the Congressional Briefing.
1 · Reply
alexandredaigneault96
alexandredaigneault96 Aug. 18 at 3:45 PM
$NGEN it's getting pathetic completely fucking pathetic. Absolutely fucking pathetic!!
1 · Reply
Tarquinjones
Tarquinjones Aug. 18 at 3:03 PM
$NGEN https://www.prnewswire.com/news-releases/breakthru-sci-launches-national-advocacy-mission-to-advance-promising-treatments-for-spinal-cord-injury-302854214.html
3 · Reply
InThaGreen
InThaGreen Aug. 18 at 11:14 AM
$NGEN petition to get NVG-291 fast-tracked for stroke patients! https://c.org/kbbNDnzLpn
3 · Reply
OculusPrime
OculusPrime Aug. 18 at 3:28 AM
$NGEN Total guess but I bet the sites that Ngen uses probably overlap the Up-Lift trial for ARC-EX. That trial enrolled 65 chronic cervical SCI patients across 14 sites in about a year’s time so each site averaged about .41 patients per month. Connect at SRLAB if I remember correctly was 1.3 patient per month. 1st few active site guesses: Shepherd Center Atlanta GA (obvious) Shirley Ryan Chicago IL (obvious) Craig Hospital Denver Colorado The Miami Project / University of Miami FL Spaulding Boston MA Kessler West Orange NJ UAB - Spain Rehabilitation Center Birmingham AL direct RESTORE evidence + prior NVG-291 experience + proven chronic cervical SCI recruitment + large SCI patient pipelines + ability to activate quickly.
2 · Reply
OldManLogan
OldManLogan Aug. 18 at 1:22 AM
$NGEN Waaaaaaaaaaaaaaaaaaay too soon...
3 · Reply
Witzorwitzout1
Witzorwitzout1 Aug. 18 at 12:57 AM
$NGEN https://www.youtube.com/watch?v=QQrzxiYbJkw
0 · Reply
DavesStockPicks
DavesStockPicks Aug. 18 at 12:29 AM
$NGEN Management sure seems intent on pushing the stock price down further. Maybe they already have a buyer lined up?
2 · Reply
Westjtter
Westjtter Aug. 17 at 10:39 PM
$NGEN Tough for the share price to run higher when the company is using their ATM to continue to build up their cash position. You can argue that it is a necessary evil and it would have been much less dilutive to ATM at a higher share price prior to the major financing....however this is pretty standard for tiny Biotechs shoring up the balance sheet right before a major event....and by that I mean the start of the ph 3. No doubt there are institutions who would love to hold a larger position but any aggressive buying would quickly push up the share price with the ongoing slow volume. Is retail selling? Nope! Are institutions selling? Nope Is the ATM selling? Yup. This is still a largely unknown stock, but having a solid balance sheet and announcing the dosing of the first ph 3 patient will really help.....meanwhile I keep picking up shares and waiting!
1 · Reply
Lytnup
Lytnup Aug. 17 at 8:28 PM
$NGEN I thought that the company had announced open label access to participants post CONNECT study, but one of the main roadblocks for patients was finding a sponsor doctor / facility to administer it….I am wondering if this time the participating locations will simply allow patients to stay on? https://youtu.be/R_tkimmD6Ig?is=QesCEqAb-fcFteoK
0 · Reply